Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 2, 2019

Innovent doses first patient in Phase III trial of tyvyt for ESCC

Innovent Biologics has dosed the first patient in the ORIENT-15 Phase III clinical trial investigating tyvyt (sintilimab injection) in combination with chemotherapy (paclitaxel and cisplatin) as first-line treatment for the treatment of patients with advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Innovent Biologics has dosed the first patient in the ORIENT-15 Phase III clinical trial investigating tyvyt (sintilimab injection) in combination with chemotherapy (paclitaxel and cisplatin) as first-line treatment for the treatment of patients with advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

The randomised, double-blind, multi-centre trial is designed to assess the efficacy and safety of the tyvyt and chemotherapy combination.

It aims to enrol and randomly distribute 640 patients in a 1:1 ratio into either experimental or control groups.

“The development of new agents for the treatment of advanced esophageal squamous cell carcinoma has been stagnant, so there is a huge unmet medical need.”

Primary objective of the ORIENT-15 trial is overall survival in all participants and in programmed cell death-1 ligand-1 (PD-L1) positive patients.

The China-based trial follows Phase Ib and II studies that examined tyvyt (sintilimab injection) in esophageal cancer patients and against paclitaxel / irinotecan as second-line therapy for treating advanced / metastatic ESCC respectively.

Innovent Biologics founder, CEO and chairman Michael Yu said: “Esophageal cancer is the third most common malignant tumour in China. The development of new agents for the treatment of advanced esophageal squamous cell carcinoma has been stagnant, so there is a huge unmet medical need.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“Based on the preliminary result or the ongoing Phase II study, we have decided to conduct ORIENT-15, a Phase III study as a first-line treatment for patients with esophageal squamous cell carcinoma.

“Our goal is to provide more effective cancer treatment options for these patients and for their families.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU